Expertise and Resources
CHCT Boston works with Principal Investigators to promote the development of novel cellular therapies by providing the necessary expertise and resources for basic investigators to transform validated hypotheses into clinical applications and to produce safe and effective cellular components for novel therapeutic clinical research protocols. Specifically, CHCT Boston has developed structures and procedures to facilitate the transition of new cell therapies to clinical practice by assisting research investigators with expertise in scale-up experimentation, cell purification, cell expansion, bio-device and cell handling under GMP conditions to develop Standard Operating Procedures (SOPs) for clinical scale processing. CHCT Boston also provides regulatory support to investigators to facilitate the processes of SOP validation, clinical trial design and Investigational New Drug (IND) application.
Current Projects at CHCT Boston
Gene Therapy for SCID-X1 Using a Self-inactivating (SIN) Gammaretroviral Vector. Principal Investigator: David Williams, MD, (Children’s Hospital Boston)
Myocardial Regeneration Using Cardiac Stem Cells Harvested From Right Atrial Appendages in Patients with Ischemic Cardiomyopathy. Principal Investigators: Piero Anversa, MD, (BWH) and Roberto Bolli, MD, (University of Louisville)
Autologous Lung Mesenchymal Progenitor Cell Therapy for Advanced Emphysema. Principal Investigator: Edward Ingenito, MD, PhD, (Brigham & Women's Hospital)
Expanded Autologous Limbal Epithelial Stem Cells for Treatment of Limbal Stem Cell Deficiency States (MEE). Principal Investigator: Ula Jurkunas, MD, (Massachusetts Eye & Ear Infirmary).
Former CHCT Boston Projects:
Autologous Invariant Natural Killer T Cells for Cancer Therapy. Steven Balk, MD, PhD, Principal Investigator, Beth Israel Deaconess Medical Center (BIDMC).
Virus Targeted Immunotherapy for Epstein-Barr Virus Associated Nasopharyngeal Carcinoma. Fred Wang, MD, PhD, Principal Investigator, Brigham and Women’s Hospital (BWH).
Artificial Antigen Presenting Cells Generate CD8+ Antigen Specific T-cells for Adoptive Immunotherapy. Principal Investigator, Marcus Butler, MD, Dana-Farber Cancer Institute (DFCI).
Prostaglandin E2 Regulates Vertebrate Hematopoietic Stem Cell Homeostasis. Principal Investigator, Len Zon, MD. (Children’s Hospital Boston).
Diaphragmatic Repair With Autologous Tendon Engineered From Mesenchymal Amniocytes. Dario O. Fauza, MD, Principal Investigator, Children's Hospital Boston (CHB).
Mesenchymal Stem Cell-based Therapy for Human Brain Tumors. Principal Investigator, Rona Carroll, Ph.D. (Brigham and Women’s Hospital).
Dendritic Cell-based Immunotherapy for Progressive Multifocal Leukoencephaloapthy. Principal Investigator, Igor Koralnik, M.D. (Beth Israel Deaconess Medical Center)
Center for Human Cell Therapy
Karp Family Research Building
One Blackfan Circle
Boston, MA, 02115
www.chct.org
copyright 2005 Center for Human Cell Therapy. All rights reserved
